However, as suggested in the recent study of Civan et al. [24], the rate of [177Lu]Lu-PSMA-617 uptake is lower and retention times of PSMA uptake are probably shorter than those in castration-resistant prostate cancer, so its efficacy is also lower due to a lower tumor dose received. This evidence concerns the gene FOLH1 and prostate cancer.